Guizhou Xinbang Pharmaceutical, the company that sold its products at a loss, is going to Hong Kong Stock Exchange.
The Hong Kong Stock Exchange IPO application wave may be imminent. Since May of this year, 22 companies have submitted IPO applications to the Hong Kong Stock Exchange, while the Shanghai and Shenzhen stock exchanges are still in a state of "0 acceptance" during the same period. As a member of the vast army of IPO applications, Taide Pharmaceutical (Zhejiang) Co., Ltd. (referred to as "Taide Pharmaceutical") is launching a sprint towards the Hong Kong Stock Exchange. The application materials showed that Taide Pharmaceutical mainly provides peptide new chemical molecular entity discovery synthesis (CRO) and peptide chemical production, manufacturing and control (CDMO) services to pharmaceutical companies. In the reporting period, Taide Pharmaceutical has already achieved profits. From 2021 to 2023.
2024 Financial Report | After the dividend ratio is close to 100%, Donga Ejiao still has 8 billion
Extravagant dividends
Review of December 24: full momentum this week, release the volume of the main funds to attack 5 shares next week.
December 24 news, the three major indices opened low, and then Prev maintained a low consolidation, the gem index led two cities down. In terms of the plate, medicine-related plates collectively rose, Chinese medicine stocks led the rise, food processing, retail and other consumer stocks were active against the trend; lithium batteries, photovoltaic, energy storage and other new energy tracks fell across the board, of which the weight fell more than 9% in the Ningde era. The index continued to weaken in the afternoon, with the gem index falling 2.7% at one point. Cultivate diamond, NFT concept stocks pull up; automobile, rare earth, fluorine chemical industry, digital currency and other sectors in the doldrums. Overall, market sentiment cooled, individual stocks showed a general downward trend, the two markets
Guangdong Lifestrong Pharmacy Targets $66 Million in Shenzhen IPO
Market Chatter: Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms
Guangdong Lifestrong Pharmacy Launches Shenzhen IPO